Department of Haematology Imperial College School of Medicine Hammersmith Hospital London, UK
j.melo@ic.ac.uk
The BCR-ABL oncoprotein of chronic myeloid leukemia can be converted into an active killer of the malignant cell when allowed to enter the nucleus. Could this lead to a three-step strategy to improve molecular targeting in the treatment of leukemia (pages 228−234)?